The North American orthobiologics market is expected to have positive growth and increasing demand in bone graft materials, according to a ReportsNReports analysis.
Here are 10 key concepts from the report:
1. The orthobiologics market in North America is driven by implant technologies innovation shifting from mechanical to biological solutions.
2. The segment began experiencing positive growth in 2012 and the markets are witnessing maximum growth because of the demand for innovation and the increased chronic arthritis with the rapidly aging population.
3. Orthobiologics is also gaining popularity because of accelerated healing capabilities, faster recoveries and reduced hospital visits.
4. The increasing rate of obesity in North American coupled with a demand for minimally invasive intervention is also driving demand for bone graft substitutes.
5. Patients are becoming more aware of orthobiologics and technological advancement in the field, and demanding "state-of-the-art" treatment.
6. Additional factors driving potential patient growth in this sector include:
• Increased sports participation and sports-related injuries
• Rising car accident incidence
• Larger geriatric population wishing to remain active longer
7. The United States contributes to around 92 percent of the orthobiologics market as of 2014.
8. The major companies in the orthobiologics market are Stryker, Zimmer, DePuy Synthes, Medtronic, Smith & Nephew, Exactech, Tornier, Biomet, Wright Medical Group and Ottobock.